Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Sharesfool.comTyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Positionfool.comThis biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.fool.comRelay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.
Nextech Trims Kymera at a Recent High — think Foolishly before acting.fool.comKymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exitfool.comClinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exitfool.comThis Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backerfool.comAgios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stakefool.comViridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Millionfool.comSpyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50%fool.comCentessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%fool.comNuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.
Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rallyfool.comFocused on precision oncology and rare genetic diseases, this biotech reported a significant insider sale amid strong one-year stock gains.
Which stocks are moving before the opening bell on Tuesday?chartmill.comBefore the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
